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NKX2.1-Related Disorders: a novel mutation
with mild clinical presentation
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Abstract
Background: A highly variable phenotype characterized by thyroid, respiratory and neurological defects has been
reported in an already established group of disorders namely NKX2.1-related disorders. We describe here the case of
an infant with a novel mutation of the NKX2.1 gene characterized by mild clinical presentation.
Aim of the study was to elucidate the genotype-phenotype correlation in our patient.
Methods: We performed genetic analysis of the NKX2.1 gene in an infant with no neonatal respiratory distress and
near-normal results at neonatal screening test for congenital hypothyroidism, choreoathetosis, ataxia and delayed
independent walking.
Results: A novel mutation of the NKX2.1 gene has been identified, that is responsible for a mild framework of
congenital hypothyroidism and neurological symptoms.
Conclusions: The frequency of congenital hypothyroidism cases associated with NKX2.1 mutations is expected to be
higher in a subgroup of patients, selected according to the neurological presentation. In these patients the analysis of
NKX2.1 mutational status is recommended.
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Background
The management of the classical form of congenital
hypothyroidism (CH) has changed thanks to the intro-
duction of neonatal screening programs, which allow
early diagnosis and replacement therapy. Over the last
few years the progressive reduction of TSH-cutoff at
neonatal screening and the advancements in the molecu-
lar analysis led to the definition of novel syndromic
forms of CH, that are associated with mild thyroid defi-
ciency [1].
Mutations of the NKX2.1 gene, previously known as
TTF1 (thyroid transcription factor 1, OMIM*600635),
mapping on chromosome 14q13, have been identified and
associated with a syndromic form of CH (OMIM*610978)
[2], initially named brain-lung-thyroid syndrome [3] due
to the broad phenotypic spectrum including a variable
combination of lung, thyroid and neurological defects.
Recently, in light of the varied manifestations of heterozy-
gous mutations of the NKX2.1 gene, the disorders have
been referred to as NKX2.1-related disorders [4]. These
disorders range from benign hereditary chorea (BHC), the
hallmark of NKX2.1-related disorders, to choreoathetosis,
congenital hypothyroidism and neonatal respiratory dis-
tress [5–13].
So far, ninety-six mutations of the NKX2.1 gene have
been reported , 70 of which are point mutations and 26
large deletions, often spanning the entire gene (HGMD
Professional 2014.2).
The NKX2.1 gene has three exons and encodes for a
member of the NK-2 family of transcription factors [14]
that mediates thyroid-specific genes transcription. During
embryogenesis the gene is expressed in the thyroid gland,
in the lung and in the forebrain, especially in the hypothal-
amic area, infundibulum and basal ganglia region [15–17].
We identified a novel mutation of NKX2.1 in an infant
showing neurological symptoms associated with near-
normal results at CH screening test, negative history of
neonatal respiratory distress and recurrent pulmonary
diseases.
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Case presentation
Child of non consanguineous parents, the patient was
born at 41 weeks of normal pregnancy, with normal
birth weight (3965 g). The family history reported two
cases of walking delay in the paternal line and several
cases of autoimmune thyroid diseases in the maternal
line. Both parents showed normal thyroid function. Neo-
natal adaptation was normal (APGAR 1° 9, 5° 10), with
no respiratory distress at birth. At neonatal screening,
TSH spot value was equal to the cut-off level (10 mUI/L).
The test was repeated on blood spot and TSH levels be-
came normal (4.4 mUI/L), thus no further analysis was
performed. In the first months of life, the infant showed a
progressive impairment in neurological development,
characterized by choreoathetosic movements, disordered
motility in the lower limbs, reduced motility of the upper
limbs, axial hypotonia and development delay. At
8 months of age the analysis revealed a mild hypertireo-
tropinemia with normal fT4 values. Thyroid ultrasound
showed a normal in situ gland. Electroencephalography
and brain MRI were normal at 12 months of age. Due to
the progressive increase of TSH levels, the infant started
the replacement therapy with L- Thyroxin at 13 months.
Growth parameters and pulse rate were recorded, electro-
cardiography was performed and blood samples were
taken in order to determine TSH and free T4 serum levels.
Biochemical and clinical features measured at follow-up
are reported in Table 1.
Serum free T4 and TSH levels were measured using a
commercial chemiluminescent assay (Bayer, Fenwald,
Germany). The clinical manifestation of the patient re-
sembled defects that have been previously associated
with mutations of the NKX2.1 gene. Therefore, DNA se-
quencing analysis was performed after obtaining in-
formed consent. Genomic DNA was extracted from
peripheral blood leukocytes of the child and his parents
and the NKX2.1 gene coding region, comprising exon
1–3 of isoform 1, as well as the exon-intron boundaries
were amplified by PCR and directly sequenced by Sanger
sequencing.
Two point mutations were identified, a heterozygous
substitution, NM_001079668:c.390C >G:p.(Tyr130Term),
resulting in a nonsense mutation and a single base ex-
change in intron 2, NM_ 001079668:c.463 + 41C > T, not
reported in the SNP database (NCBI).
The mutation was not detected in the parents, as
shown in Fig. 1. Upon administration of the replacement
therapy, the patient showed a progressive improvement
in neuromotor and growth development. Of note, the
height increased from −0,63 SDS to −0,12 SDS after one
year of treatment.
Discussion
We report the case of an infant with a novel mutation of
the NKX2.1 gene, showing neurological symptoms, with
mild impairment of thyroid function, in the absence of
neonatal respiratory distress, as a typical example of an
already established group of disorders namely NKX2.1-
related disorders.
The phenotypic spectrum of NKX2.1-related disorders
is highly variable and ranges from abnormalities in a sin-
gle organ system to any combination of brain, thyroid
and lung involvement. The neurological presentation
may be the most frequent one. In particular BHC, the
hallmark of NKX2.1-related disorders, is a classic early
finding, as suggested by previous evidence [5], and is
characterized by involuntary, irregular, jerk-like and con-
tinuous movements, frequently associated with hypo-
tonia, ataxia and choreoathetosis. In some cases BHC is
associated with respiratory distress syndrome or con-
genital hypothyroidism.
The case that we report here is characterized by mild
clinical presentation. The movement disorders of the
child were monitored starting from the first months of
life and choreathetosis was evident at 8 months. Neo-
natal CH screening showed near-normal results. A mild
form of hypothyroidism was detected in his first months
of life and was responsive to a low dose of L-Thyroxine.
No respiratory distress at birth and no respiratory symp-
toms during childhood were observed.
A novel NKX2.1 nonsense mutation (Y130X) and a
single base exchange in intron 2(c. 463 + 41C > T), not
reported in the SNP database (NCBI), were identified.
The mutations were not detected in parents, despite
the known history of walking delay in the paternal line.
This evidence indicates that we identified de novo
mutations.
The phenotype observed in our patient was mild despite
the presence of NKX2.1 gene null mutation (Y130X). This
discrepancy is not surprising in light of previous data
Table 1 Patient’s laboratoristic and neurological features before treatment with L-thyroxine
4th day 10th day 8th month 13th month
TSH spot value (mUI/L) 10 4.4
TSH serum value (Normal range in our laboratory: 0.5-5 mUI/L) 8.8 13.8
fT4 serum value (Normal range in our laboratory: 10.5–22 pmol/L) 14.8 13.4
Choreoathetosis - - + − ++
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showing the lack of genotype-phenotype correlation in
NKX2.1-related disorders [7, 11, 18, 19], likely due to the
pathogenetic role of genetic and environmental factors
that need to be further investigated [20].
The pathogenetic mechanism of the mutation, as other
truncating mutations, might involve haploinsufficiency
[2, 8, 10, 12, 21–23].
However, we cannot exclude the potential activation
of an alternative initiation site leading to a shorter
product of 268 aminoacids with intact homeobox do-
main (HD) and TD and lacking the protein N-terminal.
This product may partially preserve the protein func-
tion and therefore explain the mild phenotype of the
patient.
Several nonsense NKX2.1 mutations upstream to the
DNA binding domain, which associate with a high
phenotypic variability, have been previously reported
[2, 7, 22, 24–27].
Asmus et al. [7], Peall et al. [22] and Hamvas et al.
[24] reported three cases characterized by the same
Y144X nonsense mutation and different phenotypes.
Asmus et al. and Peall et al. reported the case of a patient
with chorea, as the only clinical presentation. Hamvas et
al. described a patient with hypotonia, development delay
and recurrent pulmonary infections, who died of a re-
spiratory sincytial virus infection.
Other nonsense NKX2.1 mutations upstream to the
DNA binding domain occuring with choreoathetosis,
Fig. 1 Chromatograms obtained from the genetic analysis of the patient and of his parents. Family tree with the corresponding chromatograms
of NKX2.1 exon 2 showing c.390C > G:p. (Tyr130Term) mutation (arrow): the father and mother are homozygous for the wild-type nucleotide
(upper panels, sense strand), the proband is heterozygous for the mutation (bottom panels, sense and antisense strands)
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CH and respiratory distress have been reported by Krude
et al. (C117X) [2], Peall et al. (W143X) [22], Ferrara et
al. (S175X) [25] and Nakamura et al. (Y98X) [26].
The G142X nonsense mutation upstream to the
NKX2.1 DNA binding domain was described by Salerno
et al. [27] in a patient with CH and respiratory distress
but not chorea, whose father was a immune carrier.
Nevertheless, the high phenotypic variability, even in
cases carrying the same mutation, is not restricted to
NKX2.1 nonsense mutations, but is a feature of all types
of NKX2.1 mutations.
Therefore, the hypothesis of the activation of an alter-
native initiation site with intact HD in the novel Y130X
nonsense mutation, upstream to the NKX2.1 DNA bind-
ing domain, seems to be remote. Functional studies are
needed to definitively rule out this hypothesis.
Conclusions
Previously published data do not allow a clear interpret-
ation of the pathogenetic role of NKX2.1 mutations in
NKX2.1-related disorders, since a number of cases were
not fully characterized for the phenotypic presentation
of choreoathetosis. Moreover, the same mutation of the
NKX2.1 gene can present with diverse phenotypes and
highly variable clinical manifestations. Our analysis sug-
gests that in the absence of severe thyroid deficit or re-
spiratory distress, neurological evaluation should guide
the patient's management. The mild hypothyroidism,
frequently observed in these cases, may not be detected
by neonatal screening. The low frequency of CH cases
due to NKX2.1 mutations that are reported in literature
is expected to be higher in a subgroup of patients se-
lected according to the neurological presentation. In
these patients, the analysis of NKX2.1 mutational status
is recommended.
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